Radiopharma Dosing Shift Shows Talent Gap

Why the Radiopharmaceutical Dosing Debate Is Widening the Specialist Hiring Gap

Dose optimisation was a hot topic at this year’s TRP Summit. It is easy to see why. Radiopharmaceutical firms are rethinking how they set doses. They are moving away from one fixed amount. Instead, they want a better balance of safety and patient benefit. For hiring managers, this shift means one thing. The people needed to make it happen are already hard to find, and the summit made that gap very clear.

A dosing debate with real hiring consequences

At the summit, Mengyao Li presented on a simple question. Should body weight change how firms dose a drug? Body weight clearly affects how a drug moves through the body. However, that does not mean the dose must change too. The real question is different. Do those differences lead to meaningful shifts in safety or efficacy?

Regulators have not agreed on an answer. Some reviews back fixed dosing, because they find no clear link between body weight and safety. Others say lower-weight patients may see less overall benefit under one fixed dose. So the debate is very much alive, and it is playing out at the highest regulatory level. In August 2025, the FDA issued draft guidance on dosage optimisation for cancer radiopharmaceuticals. This guidance extends the FDA’s Project Optimus approach into this fast-moving field. As a result, sponsors now face fresh expectations on how they justify a dose.

Why fixed dosing still wins, and what that means for skills

Fixed dosing remains the default for now. Building the evidence for personalised dosing takes time and money. It also takes the right people. Dosimetry sits at the heart of that evidence. This is the science of measuring radiation dose to tumours and healthy organs. It is also one of the hardest skills to hire for in life sciences today.

This is not just a hunch. A recent STAT News report found a “significant talent shortage” now threatens the whole field. The United States trains only five to ten new radiochemistry PhDs each year. Demand for radiopharma scientists already beats what universities can supply. If personalised dosing takes hold, that gap will grow even wider. For hiring teams, that means longer searches and smaller shortlists, starting now.

The roles radiopharma firms cannot fill alone

Many at the summit expect the field to move toward personalised dosing over time. If that happens, firms will need more than dosimetrists. They will need clinical pharmacologists who can model how patients respond. They will also need biostatisticians who can build the evidence regulators expect. In addition, they will need regulatory affairs specialists who understand how agencies read this shifting guidance.

A generalist recruiter cannot fill these roles fast. These skills sit across nuclear physics, pharmacology and regulatory science. Few people know all three well, and every radiopharma firm is chasing the same small pool. Therefore, firms that wait until a trial stalls are already behind, often by months rather than weeks.

This is where a specialist recruitment partner earns its place. At Skills Alliance, our radiopharmaceuticals team maps this talent pool every day. We track who is moving, and we track who is coming through academic programmes. We know who already holds the dosimetry or regulatory background this shift will demand. We also know the gap between someone who has touched dosimetry once and someone who can lead a full programme through FDA review.

What good hiring looks like in this space

So what should a hiring strategy look like while the science is still moving? First, build relationships with dosimetry and clinical pharmacology talent before a role opens. These specialists are rare, and they rarely respond well to a cold approach made only once a trial is under pressure. Instead, ongoing contact builds trust well ahead of need.

Second, treat regulatory affairs hires as strategic, not as an afterthought. As guidance shifts, the person reading it for your programme carries real weight. A weak hire here can slow a trial by months. Finally, work with a partner who understands both the science and the market. That combination turns a hard role into one you can actually fill.

What this means for your hiring strategy

The TRP Summit framed this dosing debate as a scientific question, and it is one. But for any team building radiopharmaceutical capability, it is also a workforce question. Whether the field lands on fixed dosing or moves toward something more personal, both paths need people who are already scarce.

It makes sense to wait and see which way the science goes. However, it does not make sense to wait on your talent pipeline. Firms that start now, with a partner who knows the science and the market, will be ready the moment the guidance settles. Specialist skills take years to build, so no one can source them overnight. The search for them has to start well before the need turns urgent.

If dose optimisation sits on your roadmap, talk to our radiopharmaceuticals team about your hiring strategy today.

By Jasmine Stewart, Associate Director, Skills Alliance